Isothermal amplification and rapid detection of *Klebsiella pneumoniae* based on the multiple cross displacement amplification (MCDA) and gold nanoparticle lateral flow biosensor (LFB)

Lina Niu¹,²☯, Fan Zhao²☯, Jinlong Chen¹☯, Jinqing Nong², Chunmei Wang², Jing Wang², Naishu Gao*, Xiaoexue Zhu², Lei Wu², Shoukui Hu²*

¹ Department of Pathogen Biology, School of Basic Medicine and Life Science, Hainan Medical University, Haikou, Hainan, China, ² Department of Clinical Laboratory, Peking University Shougang Hospital, Beijing, China

☯ These authors contributed equally to this work.

* shoukuihu@163.com

Abstract

*K. pneumoniae* is a frequent pathogen causing nosocomial infections and outbreaks. We developed a multiple cross displacement amplification (MCDA) assay for the detection of *K. pneumoniae*, which can get the positive results within 40 minutes’ isothermal amplification. Gold-nanoparticle lateral flow biosensor (LFB) and colorimetric indicators were used for the rapid readouts of MCDA amplification. The detection limit of this assay was 100 fg per reaction at 65°C, which was confirmed to be the optimal amplification temperature according to the real time turbidimeters. For specificity, all of the 30 clinical-source *K. pneumoniae* strains were positive for the MCDA, and all of the non-*K. pneumoniae* strains belonging to 31 different species were negative for this MCDA assay. To evaluate the practical applicability of this method, we assessed its detection limit for *K. pneumoniae* strains in sputum samples (24 CFU per reaction), and DNA templates of 100 sputum samples further underwent the MCDA-LFB tests. All of the sputum samples being positive for *K. pneumoniae* (30/100) with the culture method were successfully identified with the MCDA assay, the detection power of which was higher than that of polymerase chain reaction (PCR) (25/100). Thus, the MCDA test for *K. pneumoniae* combined with the gold nanoparticle LFB as the results readout scheme, are simple, specific, and sensitive methods for the rapid diagnosis of *K. pneumoniae* in clinical samples.

Introduction

*K. pneumoniae* is a gram negative opportunistic pathogen belonging to *Klebsiella* spp. *K. pneumoniae* mainly attack the immunocompromised populations, manifested as pneumonia, meningitis, bacteremia, sepsis, urinary tract infection and focal infections [1,2]. *K. pneumoniae* is widely present in the hospital environment of hospitals, even in the medical equipment like bronchoscopy, duodenoscopy, gastroscopy and more [2–4].
Moreover, it can colonize in the gastrointestinal tract asymptotically and on the hands of hospitalized patients or the hospital personnels, serving as reservoirs and carriers for this conditioned pathogen [5]. Thus, K. pneumoniae is one common reason for the nosocomial infections, especially in the intensive care units [6]. In the past two decades, multi-drug resistance of K. pneumoniae has increased substantially, which offer advantages over other antimicrobial-sensitive bacteria in the hospital and patients [6]. K. pneumoniae often contaminates hospital equipment and hospitalized patients who have shared the contaminated equipment; therefore, nosocomial outbreaks caused by K. pneumoniae have been frequently reported among the hospitalized patients [3,4,7]. Thus, prophylaxis measures, especially for sensitive and rapid diagnostic assays, are required for the control of healthcare-associated infections caused by K. pneumoniae.

Multiple cross displacement amplification (MCDA) was a nucleotide-based isothermal amplification assay devised by Wang et al. (Patent number CN201510280765.X) [8]. This method has superior performance compared to traditional polymerase chain reaction (PCR). Rapidity and simplicity in operation are the outstanding features of MCDA, which merely requires for a thermostatic environment (ranging from 60˚C to 68˚C) of less than 40 minutes for amplification [8]. These characteristics will fit in well with the field investigations especially when experimental settings are limited. Besides, the high concentration of primers in the reaction system allows for a high sensitivity of this method, the detection limit of which can reach 10 fg/μL [9]. Moreover, MCDA is economic friendly with each reaction system costs an average of $3.5, making it possible for the widely application in the poor-resource settings [10].

There were many techniques developed for the verification of positive amplification [10]. Gel electrophoresis and imaging is the traditional method being widely used, but it is laborious, time consuming and equipment demanding. Real-time fluorescent instruments and real-time turbidimeters are quick and quantitative, but the apparatuses are expensive and unportable, which limit their application in poor-source settings and field investigations. Colorimetric indicators were quick and convenient, but the colorimetric indicators were subjective and sometimes may be difficult to determine the results [11]. The gold nanoparticle lateral flow biosensor (LFB) is a novel method to detect specific DNA fragments, which is based on the binding of antibodies (embedded on the LFB) and haptens (labeled on the 5’ side of primers) [12–14]. Recently, LFB was used for reporting MCDA results [9–11,15]. When there were positive amplification products, the amplified sequences labeled with haptens will be bound to the antibodies embedded on the test line, showing the red color. In comparison with other method for indicating MCDA results, LFB is relatively simple, quick and objective.

Here, we developed a MCDA detection assay for K. pneumonia, which is a common cause for the nosocomial infections. The optimal amplification temperature was screened. Sensitivity, specificity and the clinical application of the K. pneumonia-MCDA assay were assessed. LFB and colorimetric indicators were applied as the main methods for the identification of positive amplification products, which were confirmed with turbidimeters and gel electrophoresis [9,11].

Materials and methods

Design of MCDA primers

The five pairs of primers for the isothermal amplification and identification of K. pneumoniae were designed according to the principle of MCDA developed by Wang et al. [9,11]. Two widely used softwares (PrimerExplorer V4 and Primer Primer 5.0) were used to design the MCDA primers on the rcsA gene, which was specific for K. pneumoniae and had been used for the genome-based identification of this pathogen (GenBank accession No. NC_012731.1) [16].
Specificity of the primers designed was verified with the nucleotide BLAST (Basic Local Alignment Search Tool) of the GenBank database. The location and the sequence of each primer were indicated in Fig 1 and Table 1, respectively. Moreover, the 5´- ends of the primers C1 and D1 were labeled with biotin and fluorescein isothiocyanate (FITC), respectively. All oligomers were synthesized by Ruiboxingke. C., Ltd. (Beijing, China).

The *K. pneumoniae*-MCDA-LFB assay

The standard MCDA assay was performed generally in accordance with that of Wang et al. [9,11]. It was carried out in a 25 μL reaction system including: 0.4 μM/L each of F1 and F2, 1.6 μM/L each of CP1 and CP2, 0.8 μM/L each of C1 (C1⁺), C2, R1, R2, D1(D1⁺) and D2, 12.5 μL 2 x Reaction Buffer, 1 μL Bst DNA polymerase (10 U) and 1 μL DNA templates. The reaction buffer and the Bst DNA polymerase were obtained from the isothermal amplification kits (Haitaizhengyuan, Beijing, China). Mixtures containing 1 μL genomic DNA of *Staphylococcus aureus* (67.5 ng/μL) and *Salmonella typhii* (130.0 ng/μL) were used as the negative controls. One mixture containing 1 μL of double distilled water was used as the blank control.

The reaction systems were isothermally amplified at 65˚C (which was verified to be the optimal amplification temperature with high efficiency), followed by 85˚C for 5 minutes to terminate the amplification. Amplicons were read by LFB detection, colorimetric indicators, and gel electrophoresis. Preparation of LFB and detection using the biosensor were as previously described.

**Table 1. Primers of the MCDA assay for the identification of *K. pneumoniae*.**

| Primers⁺ | Sequences and modifications (5´-3´) | Lengthᵇ |
|----------|-----------------------------------|---------|
| F1       | CTAAAATACAAAAACACCAGTGTAG         | 25 nt   |
| CP1      | CCATCCACATTGCGACGATTTTGAGGGCAGTTACTTTTACGGACATT | 47 mer |
| C1⁺      | Biotin-C CATCCACATTGCGACGATTTTGAGGGCAGTTACTTTTACGGACATT | 25 nt |
| D1⁺      | FITC-TCTGTTTTATCTCAGTGAC          | 19 nt   |
| R1       | AGATTGGGAAGGTACCATGC              | 20 nt   |
| R2       | CAACGGCAAATGACAATCAAAG            | 21 nt   |
| D2       | AGAAATACAAAACCCGATAAAG            | 23 nt   |
| C2       | CGAAGACGGATACGTCGCGATAAA          | 22 nt   |
| CP2      | CGAAGACGGATACGTCGCGATAAA          | 45 mer  |
| F2       | GTGATGTTTTCGGTCGAC                | 18 nt   |

⁺C1⁺, 5´-labeled with biotin for the MCDA-LFB assay; D1⁺, 5´-labeled with FITC for the MCDA-LFB assay.

ᵇ nt refers to the nucleotide; mer refers to monomeric.

https://doi.org/10.1371/journal.pone.0204332.t001
described by Wang et al. [10,15]. On the LFB, 0.2 μL of the MCDA products followed by 100 μL of the running buffer (0.01 M phosphate-buffered saline, pH 7.4 with 1% Tween 20) were deposited on the sample pad. After 2 minutes, two red lines (the test line and the control line) are observed in positive reactions, but only the control line is visualized for the negative and blank control reactions (Fig 2A). It should be noted that during the LFB reactions, the LFB pads should be tilted with the sample pads being placed lower than the absorbent pads for about 30°, which will be in favor of the siphon actions. When using colorimetric indicators, the color of the positive reactions will remain to be blue, while the negative and blank controls will fade into colorless (Fig 2B). In 2% agarose gel electrophoresis, the MCDA amplification products were running at 80 volts for 1 hour. The gel image was captured under ultra violet with the GEL DOC XR (Bio-Rad, America). A ladder of multiple bands was observed for the positive amplifications, but the ladder bands were not observed in the negative and blank controls (Fig 2C).

**The optimal amplification temperature**

In order to screen the optimal temperature for the MCDA assay, the identical reaction systems (10 pg of ATCC2146) were amplified at temperatures (60˚C to 67˚C). The real time turbidity of each reaction was recorded, with >0.1 as the threshold value for the positive reactions at 650 nm of optical density. DNA of *Staphylococcus aureus* (67.5 ng per reaction) was used as the negative control and distilled water as the blank control. The temperature that enables the amplification completed efficiently with high amplification products, were selected as the optimal temperature for the MCDA test of *K. pneumoniae* specific gene rcsA. The optimal temperature screening experiment was repeated three times. In order to confirm the optimal amplification temperature, we repeated the temperatures of 63˚C, 64˚C, 65˚C and 66˚C (which were found to be the potential candidates of the optimal temperature) for another 10 times.

**The sensitivity of *K. pneumoniae*-MCDA assay**

To assess the sensitivity of the MCDA assay for the identification of *K. pneumonia*, the DNA template of ATCC2146 was serially diluted from 10 ng/μL to 0.1 fg/μL with distilled water. Real time turbidity of eight different DNA content (10 ng, 10 pg, 1 pg, 100 fg, 10 fg, 1 fg, 0.1 fg, and distilled water) were measured to identify the limit of detection of the MCDA assay which was empirically ranging from 1 pg to 1 fg according to Wang et al.’s [15,17]. DNA templates of *Staphylococcus aureus* and *Salmonella typhii* were used as the negative controls (NC), and distilled water as the blank control (BC). The amplification products were further verified with
the colorimetric indicators, gel electrophoresis and the LFB method. The sensitivity evaluation experiment was repeated three times.

Moreover, we evaluated the sensitivity of the MCDA-LFB assay to detect the *K. pneumoniae* strains in mixture of other non-*K. pneumoniae* strains. We prepared the MCDA reactions containing different concentration of *K. pneumoniae* (ranging from 10 ng to 0.1 fg per reaction, and the blank control). Meanwhile, 1 μL DNA templates of one non-*K. pneumoniae* strain (i.e. *Staphylococcus aureus* at 67.5 ng/μL, *Salmonella typhi* at 130.0 ng/μL, *Acinetobacter baumannii* at 55.3 ng/μL, and *Streptococcus pneumoniae* at 82.2 ng/μL) was added into the reactions.

The specificity of *K. pneumoniae*-MCDA-LFB assay

To evaluate the specificity of the MCDA assay, the DNA templates of 31 strains of *K. pneumoniae* including ATCC2146 and 30 clinical-source *K. pneumoniae* strains, as well as 35 non-*K. pneumoniae* strains were tested for the MCDA assay. DNA of the pure culture strains were extracted with the DNA extraction kits (Tiangen, Beijing). We initially analyzed the amplification products using the colorimetric indicators. Furthermore, the amplification products from 24 strains, including 12 clinical-source *K. pneumoniae* strains and 12 non-*K. pneumoniae* strains were selected randomly for verification using the LFB test. The specificity assessment was confirmed three times.

The clinical samples evaluation for the MCDA based identification of *K. pneumoniae*

To evaluate the practical application of the MCDA-LFB assay, we assessed its detection limit for *K. pneumoniae* strains in sputum samples, by artificially adding the diluted ATCC2146 into the sputum samples. Briefly, one single colony of the ATCC2146 on the Columbia sheep blood agar, was inoculated into 5 ml of the brain heart infusion and incubated at 37°C (220 rpm/min) for about 14 hours. Then, 100 μL of the bacteria suspension was streaked into 5 ml of brain heart infusion and incubated (37°C, 220 rpm/min) until the optical density (OD) at 600 nm reached to 0.6. The bacteria suspension (OD 0.6) was then 10-fold serially diluted (from $10^{-1}$ to $10^{-10}$) with 0.01 M phosphate buffered saline, pH7.4. The aliquots of 100 μL dilutions ($10^{-5}$ to $10^{-7}$) were spread in triplicate onto the Columbia blood plate medium agars and incubated at 37°C. The number of colony forming units (CFU) was counted after 24 hours’ culture. Meanwhile, aliquots of 100 μL diluted suspensions were added into the sputum samples, which have been confirmed to be negative for this pathogen with the culture method in advance. The concentration of the ATCC2146 was adjusted to $2.4 \times 10^6$, $2.4 \times 10^7$, $2.4 \times 10^8$, $2.4 \times 10^9$, $2.4 \times 10^{10}$ CFU/ml in the sputum samples. DNA templates of the artificially contaminated sputum samples (100 μL) were extracted and dissolved in 10 μL of Qiagen elution buffer (Qiagen, Germany). Then, 1 μL of the DNA templates were tested with both the MCDA-LFB. And the PCR method was used as comparison, the primers of which were indicated in S1 Table. The limit of detection (LOD) evaluation assay in the sputum samples was performed triplicate independently.

Moreover, 100 human sputum samples from the Department of Clinical Laboratory, Peking University Shougang Hospital, were collected and extracted for the DNA with the DNA Microbiome Kits (Qiagen, Germany) since March 2017 to June 2017. All patients who provided samples gave written informed consent. The clinical laboratory of Shougang Hospital has access to the information that could identify individual participants during the samples collection. This study was approved by the Ethics Committee of Shougang Hospital, and conducted according to the medical research regulations of the Ministry of Health, China. These samples were previously identified by the culture and biochemical method (the reference
method) and stored at −70°C until use in the MCDA-LFB assay. By the reference method, 30
(30%) of the 100 samples were identified as *K. pneumoniae*-positive, while the remainders
were identified as containing other bacteria or negative. The other bacteria included *Acinetobacter baumannii*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Staphylococcus hominis*
with the culture methods. DNA templates of the sputum samples were tested with the
MCDA-LFB assay by adding 1 μL of the DNA templates of the sputum samples. In addition,
the PCR amplification test for *K. pneumoniae* was performed to compare with the results of
MCDA-LFB test and the reference method.

**Statistical analysis**
Sensitivity of the MCDA-LFB assay or PCR for clinical sample detection was computed by
Number of true positive/ (Number of true positive + Number of false negative) ×100%. Speci-
cificity of the MCDA-LFB assay or PCR for clinical detection was computed by Number of true
negative/ (Number of true negative + Number of false positive) ×100%. The receiver-operating
characteristic (ROC) curves analysis were performed in detection result for the 100 clinical
samples by MCDA-LFB assay or PCR. Statistical Program for Social Sciences (SPSS) software
version 20.0 (Inc., Chicago, IL, USA) was used for computation.

**Results**
**The MCDA assay and the LFB verification for *K. pneumoniae***
We found one of the three sets of primers designed was applicable for the identification of *K.
*pneumoniae* with the negative controls and the blank control being negative using the three
monitoring methods. For the positive reactions, there were two red bands on the LFBs (Fig
2A), the color of the reaction remain to be blue (Fig 2B), and the electrophoresis gel showed
ladder bands (Fig 2C). As there were five pairs of primers working on the target sequence at
different binding sites [8], the MCDA reactions produced amplification products of different
sizes showing ladder bands in the electrophoresis gel (Fig 2C). During the isothermal amplifi-
cation process, the cross primers of CP1 and CP2 produced amplification products of increas-
ing sizes as long as 1000 bp or more. For the negative reactions, there was only one red band
on the control line; the reactions faded into colorless; and there were no ladder bands as large
as 1000 bp by electrophoresis.

**The optimal amplification temperature**
We identified the optimal amplification temperature (ranging from 60°C to 67°C of the *K.
pneumoniae*-MCDA assay). We found that 65°C was the best candidate, the turbidity of which
occurred earlier than the other temperatures with amplification products being relatively
higher (Fig 3). In order to confirm the optimal amplification temperature, we repeated the
temperatures of 63°C, 64°C, 65°C and 66°C for another 10 times, with the real time turbidity
recorded. There were 9 times indicated that 65°C was the optimal temperature, the turbidity of
which occurred earlier than the other temperatures with amplification products being rela-
tively higher. And there was one time that no obvious difference was observed among the tur-
bidity lines of the four temperatures. It suggested that 65°C was the optimal amplification
temperature.

**The sensitivity of the *K. pneumoniae*-MCDA-LFB assay**
By measuring the turbidity of the reactions with different DNA content (10 ng, 10 pg, 1 pg,
100 fg, 10 fg), the detection limit of the *K. pneumonia*-MCDA assay was 100 fg (Fig 4A). The
results were in accordance with that of colorimetric indicators, gel electrophoresis and LFB results (Fig 4).

We also assessed the sensitivity of the \textit{K. pneumoniae}-MCDA-LFB assay when in mixture of other non-\textit{K. pneumoniae} strains, by 1 μL DNA of non-\textit{K. pneumoniae} strain (\textit{Staphylococcus aureus} at 67.5 ng/μL, \textit{Salmonella typhii} at 130.0 ng/μL, \textit{Acinetobacter baumannii} at 55.3 ng/μL, and \textit{Streptococcus pneumoniae} at 82.2 ng/μL) into 8 reactions containing different concentration of ATCC2146 (10 ng, 10 pg, 1 pg, 100 fg, 10 fg, 1 fg, 0.1 fg and distilled water). The LOD for the \textit{K. pneumoniae}-MCDA assay remained to be 100 fg (S1 Fig).

The specificity of the \textit{K. pneumoniae}-MCDA-LFB assay

By testing the 30 clinical-source \textit{K. pneumoniae} strains and 35 non-\textit{K. pneumoniae} strains, all of the \textit{K. pneumoniae} strains showed positive results with the color remained to be blue, while

https://doi.org/10.1371/journal.pone.0204332.g003

https://doi.org/10.1371/journal.pone.0204332.g004
all of the 35 non-\textit{K. pneumoniae} reactions faded into colorless after the amplification (Table 2). When using the LFB to test the amplification products of the randomly selected 24 strains for validation, the results are in accordance with those using the colorimetric indicators. For the

| ID    | Strains                  | Sources                          | MCDA assay result | Selected for LFB validation (n) |
|-------|--------------------------|----------------------------------|-------------------|---------------------------------|
| 1     | \textit{Klebsiella pneumoniae} | ATCC2146                         | P                 | 1                               |
| 2–17  | \textit{Klebsiella pneumoniae} | Isolated strains sputum          | P                 | 5                               |
| 18–25 | \textit{Klebsiella pneumoniae} | Isolated strains from urine      | P                 | 2                               |
| 26–27 | \textit{Klebsiella pneumoniae} | Isolated strains from blood      | P                 | 1                               |
| 28–29 | \textit{Klebsiella pneumoniae} | Isolated strains from pharyngeal swabs | P | 1                               |
| 30    | \textit{Klebsiella pneumoniae} | Isolated strains from puncture fluid | P | 1                               |
| 31    | \textit{Klebsiella pneumoniae} | Isolated strains from a wound    | P                 | 1                               |
| 32    | \textit{Acinetobacter baumanii} | Isolated strains from sputum     | N                 | 0                               |
| 33    | \textit{Aeromonas caviae} | Isolated strains (U)\textsuperscript{b} | N                 | 1                               |
| 34    | \textit{Aeromonas sobria} | Isolated strains (U)             | N                 | 0                               |
| 35    | \textit{Bacillus cereus} | Isolated strains (U)            | N                 | 1                               |
| 36    | \textit{Citrobacter braakii} | Isolated strains (U)            | N                 | 1                               |
| 37    | \textit{Citrobacter freundii} | Isolated strains (U)           | N                 | 0                               |
| 38    | \textit{Citrobacter youngae} | Isolated strains (U)            | N                 | 0                               |
| 39    | \textit{Corynebacterium stationis} | Isolated strains from the environment | N | 1                               |
| 40    | \textit{Corynebacterium ammoniagenes} | Isolated strains from the environment | N | 0                               |
| 41    | \textit{Enterobacter sakazakii} | Isolated strains from feces    | N                 | 1                               |
| 42    | \textit{Enteroaggregative E. coli (EAEC)} | Isolated strains from feces | N | 0                               |
| 43    | \textit{Enteroinvasive Escherichia coli (EIEC)} | Isolated strains from feces | N | 0                               |
| 44    | \textit{Enteropathogen Escherichia coli (EPEC)} | Isolated strains from feces | N | 0                               |
| 45    | \textit{Enterotoxigenic Escherichia coli (ETEC)} | Isolated strains from feces | N | 1                               |
| 46    | \textit{Shigatoxin-producing E. coli (STEC)} | Isolated strains from feces | N | 0                               |
| 47    | \textit{Listeria ivanovii} | Isolated strains (U)            | N                 | 0                               |
| 48    | \textit{Listeria monocytogenes} | Isolated strains from blood    | N                 | 1                               |
| 49–51 | \textit{Pseudomonas aeruginosa} | Isolated strains from sputum      | N | 0                               |
| 52    | \textit{Proteus mirabilis} | Isolated strains from the environment | N | 0                               |
| 53    | \textit{Providencia rettgeri} | Isolated strains from the environment | N | 0                               |
| 54    | \textit{Salmonella enteric} | Isolated strains from feces    | N                 | 1                               |
| 55    | \textit{Salmonella typhi} | Isolated strains from feces    | N                 | 0                               |
| 56    | \textit{Shigella dysenteriae} | Isolated strains from feces    | N                 | 0                               |
| 57    | \textit{Shigella flexneri} | Isolated strains from feces    | N                 | 1                               |
| 58    | \textit{Shigella sonnei} | Isolated strains from feces    | N                 | 0                               |
| 59    | \textit{Staphylococcus cohnii} | Isolated strains from the environment | N | 0                               |
| 60    | \textit{Staphylococcus sciuri} | Isolated strains from the environment | N | 0                               |
| 61    | \textit{Staphylococcus aureus} | Isolated strains from sputum | N | 1                               |
| 62    | \textit{Staphylococcus epidermidis} | Isolated strains (U) | N | 0                               |
| 63    | \textit{Staphylococcus saprophyticus} | Isolated strains (U) | N | 0                               |
| 64    | \textit{Streptococcus pneumoniae} | Isolated strains from sputum | N | 1                               |
| 65    | \textit{Streptococcus suis} | Isolated strains from feces    | N                 | 1                               |
| 66    | \textit{Vibrio vulnificus} | Isolated strains (U)            | N                 | 0                               |

\textsuperscript{a} MCDA assay result: detected using the colorimetric indicator method. P, positive for the MCDA assay; N negative.

\textsuperscript{b} U: unknown.

https://doi.org/10.1371/journal.pone.0204332.t002
LFBs of the *K. pneumoniae* strains, there were two lines on the LFB pads, including the test line and the control line. For the non-*K. pneumoniae* strains of different species, there was only one red mark in the control line on the LFB pads (Fig 5). Furthermore, the MCDA-LFB results of the *K. pneumoniae* and non-*K. pneumoniae* strains were the same in the triplicate repeats.

The clinic samples evaluation for the MCDA based identification of *K. pneumoniae*

In order to evaluate the practical application of the *K. pneumoniae*-MCDA-LFB assay, we assessed its LOD for *K. pneumoniae* strains in sputum samples. The MCDA-LFB assay was able to generate positive results when the number of *K. pneumoniae* strains in the sputum samples was more than $2.4 \times 10^3$ CFU/ml (24 CFU per reaction) (S2 Fig). It was 100 times more sensitive than the PCR methods, the LOD of which was $2.4 \times 10^5$ CFU/ml (2400 CFU per reaction).

Furthermore, DNA templates of 100 sputum samples from the hospitalized patients underwent the *K. pneumoniae*-MCDA-LFB test, with 30 sputum samples being identified positive for this pathogen. The sputum samples being cultured positive for other bacteria (including *Acinetobacter baumannii*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Staphylococcus hominis*) were negative for the *K. pneumoniae*-MCDA-LFB assay. The results of the *K. pneumoniae*-MCDA tests were in complete agreement with that of the culture method. In contrast, the PCR assay only identified 25 positive samples (Table 3). Thus, the sensitivity and specificity for *K. pneumoniae*-MCDA-LFB assay were both 100%, while they were 83.3% and 100% for PCR, respectively (S3 Fig).
Discussion

*K. pneumoniae* is a well-recognized reason for the nosocomial infections [1]. Early and rapid diagnosis of this pathogen in the clinical samples of patients like sputum, blood, urine and other fluids, will help control the development of infections, which is utmost important for the critical patients. Many *K. pneumoniae* outbreaks were found to be associated with the environmental or equipment contaminations, e.g. in the bronchoscopy, endoscopy, and water sink in the ICU [3,4,7,18]. A rapid and simple detection method with high sensitivity will be useful for the rapid identification of *K. pneumoniae* infections and the surveillance of this pathogen in the healthcare environment. As far as we know, reports about rapid detection assays of *Klebsiella pneumoniae* is few, all of which were based on the technique of loop mediated isothermal amplification (LAMP) [16,19]. There were 2 to 2.5 pairs of sequences working on the target sequence with the LAMP method, making it more rapid and sensitive than the normal PCR method [19,20]. It has been reported that by adding additional primers for the isothermal amplification, the sensitivity can increased and the amplification time can be reduced [21,22]. Thus, we introduced the technique of MCDA, which has five pairs of primers working on the target sequence at the same time, for the rapid detection of *K. pneumoniae* targeting the *rcsA* gene [8]. *RcsA* gene, which regulates the capsule production of *K. pneumoniae*, had been reported to be one specific gene for this pathogen [16,23]. The MCDA detection of *K. pneumoniae* could be completed within 40 minutes at 65˚C, which is similar to the other MCDA-based assays [15,17].

Besides, this study introduced the simple, rapid and objective gold-nanoparticle-based LFB for the results reading. The same with Wang et al.’s results, all the *K. pneumoniae* positive MCDA products were successfully identified with LFB, with two red lines occurred within 2 minutes [9]. By identifying the amplification products labeled with FITC and biotin, the results recognized by LFB are relatively more objective and reliable than that of turbidimeters and colorimetric indicators [9]. Although the gel electrophoresis method could distinguish the specific amplification and non-specific amplification, it is laborious and equipment demanding. Considering the high work load of diagnosis and examination in the clinical laboratory, LFB will be one efficient candidate for the results reading of either normal PCR or isothermal amplification approaches.

The detection limit of the *K. pneumoniae*-MCDA assay was determined as 100 fg. Other MCDA based studies also found that the threshold of detection is ranging from 1 pg to 10 fg [9,17]. In fact, the isothermal amplification assays can be more sensitive by removing the carryover contamination and non-specific amplification, with the further lower concentration of DNA being recognized after longer amplification time [22].

The 100% positivity of the 30 clinical-source *K. pneumoniae* strains and the 100% negativity of the 35 non-*K. pneumoniae* strains indicated that the MCDA primers based on *rcsA* gene were specific to *K. pneumoniae*. However, carryover contamination is a great concern for genome template based identification assays, especially for the isothermal amplification
methods with high concentration of primers. We noted examples of false positive results occurring when the amplification was prolonged for more than 40 minutes. Limiting the amplification time has been suggested by Wang et al. to reduce the carryover amplification [22]. According to the turbidity graph of sensitivity (Fig 4A), the amplification of 100 fg DNA reached the positive threshold of 0.1 after 25 minutes. Thus, we suggest the amplification time of no more than 40 minutes, in order to reduce the interference of carryover amplification and non-specific amplification. And it was recently found that the carryover contamination can be removed by adding the Antarctic thermolabile uracil-DNA-glycosylase into the reaction system before amplification [22].

We evaluated the LOD of the MCDA-LFB in clinical samples by artificially contaminating the K. pneumoniae-negative sputum sample with the ATCC2146 of different concentrations. Using the DNA of the sputum samples as templates, the LOD of the K. pneumoniae-MCDA-LFB assay was 24 CFU per reaction, which was 100-fold more sensitive than the PCR method. Other reports also showed that the MCDA-based assay was more sensitive than the PCR method in clinical or food samples [9,24]. The sensitivity of the MCDA assay did not decrease in mixture of other non-K. pneumoniae strains of high concentration. Moreover, we evaluated the practical applicability of MCDA for K. pneumoniae in 100 clinical sputum samples. All of the samples positive for the K. pneumoniae with culture method were successfully identified with the MCDA assay. While only 25 samples were recognized with the PCR method. This may be attributed to the lower sensitivity of PCR method in sputum samples. The sputum samples being cultured positive for other pathogenic bacteria were negative for the K. pneumoniae-MCDA-LFB assay, in agreement with the specificity evaluation results. The detection limit of this assay did not decrease when the K. pneumoniae strains were in mixture of the other strains. Thus, the K. pneumoniae-MCDA-LFB assay can be used as a candidate for the rapid identification of this pathogen in the original samples like sputum. Traditional culture requires for at least two days and is equipment dependent, isothermal amplification methods such (loop-mediated isothermal amplification) LAMP has been applied in the identification of infection in the clinical samples [25,26]. The results of this study suggested that the MCDA method could be used to identify K. pneumoniae infections.

Conclusion

We developed a rapid and simple isothermal amplification and identification assay for K. pneumoniae based on the proof-of-concept MCDA and LFB. DNA templates of the K. pneumoniae strains and the non-K. pneumoniae strains were successfully recognized with MCDA. The detection limit of this assay is 100 fg which can be recognized after 25 minutes of isothermal reaction at 65°C. The MCDA-LFB assay could efficiently identify K. pneumoniae in clinical samples such as sputum.

Supporting information

S1 Table. PCR primers for rcsA gene to detect K. pneumoniae.

S1 Fig. Sensitivity of the MCDA-LFB assay to detect K. pneumoniae in mixtures with other non-K. pneumoniae strains. LFBs of 1 to 8 refer to MCDA reactions containing different DNA concentrations of K. pneumoniae (10 ng, 10 pg, 1 pg, 100 fg, 10 fg, 1 fg, 0.1 fg, and the blank control) and 67.5 ng of Staphylococcus aureus per reaction (A), 130.0 ng of Salmonella typhi per reaction (B), 55.3 ng of Acinetobacter baumannii per reaction (C), and 82.2 ng of Streptococcus pneumoniae per reaction (D). The detection limit of MCDA-LFB assay was 100

PLOS ONE | https://doi.org/10.1371/journal.pone.0204332 October 1, 2018
fg, showing both the test line and the control line on the LFBs. MCDA, multiple cross displacement amplification; LFB, gold nanoparticle lateral flow biosensor.

(TIF)

S2 Fig. Detection limit of the K. pneumoniae MCDA assay in artificially contaminated sputum samples. MCDA reactions containing different concentrations of K. pneumoniae reference strain ATCC2146 (24,000 CFU, 2,400 CFU, 240 CFU, 24 CFU, and 2.4 CFU per reaction) using Staphylococcus aureus and Salmonella typhii as negative controls (NC) and distilled water as blank control (BC). The LOD in sputum samples was 24 CFU per reaction according to the real-time turbidimeter (A). The amplification products were electrophoresed in 2% agarose gel, with the reactions containing 24,000 CFU to 24 CFU of K. pneumoniae showing ladder bands (B). This was in agreement with the results of the colorimetric indicators and LFBs, the positive reactions of which showed a blue color and two red bands on the LFBs, respectively (C, D). MCDA, multiple cross displacement amplification; LFB, gold nanoparticle lateral flow biosensor.

(TIF)

S3 Fig. The ROC curve analysis for the MCDA-LFB assay and PCR in 100 clinical sputum samples. The sensitivity and specificity for K. pneumoniae-MCDA-LFB assay (solid line) were both 100%, while they were 83.3% and 100% for PCR (dash line). ROC, receiver-operating characteristic; MCDA, multiple cross displacement amplification; LFB, gold nanoparticle lateral flow biosensor.

(TIF)

Author Contributions

Conceptualization: Lina Niu, Fan Zhao, Shoukui Hu.

Data curation: Fan Zhao, Jinlong Chen, Jinqing Nong, Jing Wang.

Formal analysis: Lina Niu.

Funding acquisition: Lina Niu, Fan Zhao, Shoukui Hu.

Investigation: Jinqing Nong, Naishu Gao, Xiaoxue Zhu, Lei Wu.

Methodology: Lina Niu, Fan Zhao, Jinlong Chen, Chunmei Wang, Jing Wang, Shoukui Hu.

Project administration: Shoukui Hu.

Resources: Jinlong Chen, Jinqing Nong, Chunmei Wang, Jing Wang, Naishu Gao, Xiaoxue Zhu, Lei Wu, Shoukui Hu.

Supervision: Shoukui Hu.

Validation: Lina Niu, Jinlong Chen, Jinqing Nong.

Visualization: Lina Niu, Fan Zhao, Chunmei Wang, Naishu Gao, Lei Wu.

Writing – original draft: Lina Niu, Fan Zhao, Jinlong Chen.

Writing – review & editing: Lina Niu, Fan Zhao, Shoukui Hu.

References

1. Bialek-Davenet S, Criscuolo A, Aïlloûd F, Passet V, Jones L, Delannoy-Vieillard A-S, et al. Genomic Definition of Hypervirulent and Multidrug-Resistant Klebsiella pneumoniae Clonal Groups. Emerg Infect Dis. 2014; 20(11): 1812–1820. https://doi.org/10.3201/eid2011.140206 PMID: 25341126
2. Kontopodi F, Giamarelou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, et al. Infections caused by carbapenem-resistant *Klebsiella pneumoniae* among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014; 20(2): O117–O123. https://doi.org/10.1111/1469-0691.12341 PMID: 23992130

3. Kola A, Pliening B, Pape U-F, Veltzke-Schlieker W, Kaase M, Geffers C, et al. An outbreak of carbapenem-resistant OXA-48—producing *Klebsiella pneumonia* associated to duodenoscopy. Antimicrob Resist Infect Control. 2015; 4: 8. https://doi.org/10.1186/s13756-015-0049-4 PMID: 25815166

4. Naas T, Cuzon G, Babics A, Fortineau N, Boytchev I, Gayral F, et al. Endoscopy-associated transmission of carbapenem-resistant *Klebsiella pneumoniae* producing KPC-2 β-lactamase. J Antimicrobial Chemother. 2010; 65(6): 1305–1306. https://doi.org/10.1093/jac/dkq117 PMID: 20382724

5. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmoré TN, et al. Tracking a Hospital Outbreak of Carbapenem-Resistant *Klebsiella pneumoniae* with Whole-Genome Sequencing. Sci Transl Med. 2012; 4(148): 418ra116. https://doi.org/10.1126/scitranslmed.3004129 PMID: 22914622

6. Sanchez GV, Master RN, Clark RB, Fyyaz M, Duvvuri P, Ekta G, et al. *Klebsiella pneumoniae* Antimicrobial Drug Resistance, United States, 1998–2010. Emerg Infect Dis. 2013; 19(1): 133–136. https://doi.org/10.3201/eid1901.120310 PMID: 23260464

7. Starlander G, Melhus Å. Minor outbreak of extended-spectrum β-lactamase-producing *Klebsiella pneumoniae* in an intensive care unit due to a contaminated sink. J Hosp Infect. 2012; 82(2): 122–124. https://doi.org/10.1016/j.jhin.2012.07.004 PMID: 22871394

8. Wang Y, Wang Y, Ma A-J, Li D-X, Luo L-J, Liu D-X, et al. Rapid and Sensitive Isothermal Detection of Nucleic-acid Sequence by Multiple Cross Displacement Amplification. Sci Rep. 2015; 5: 11902. https://doi.org/10.1038/srep11902 PMID: 26154567

9. Wang Y, Li H, Wang Y, Li H, Luo L, Xu J, et al. Development of multiple cross displacement amplification label-based gold nanoparticles lateral flow biosensor for detection of *Listeria monocytogenes*. Int J Nanomedicine. 2017; 12: 473–486. https://doi.org/10.2147/IJN.S123625 PMID: 28138243

10. Wang Y, Li H, Li D, Li K, Wang Y, Xu J, et al. Multiple Cross Displacement Amplification Combined with Gold Nanoparticle-Based Lateral Flow Biosensor for Detection of *Vibrio parahaemolyticus*. Front Microbiol. 2016; 7: 2047. https://doi.org/10.3389/fmicb.2016.02047 PMID: 28066368

11. Wang Y, Wang Y, Wang H, Xu J, Ye C. A label-free technique for accurate detection of nucleic acid–based self-avoiding molecular recognition systems supplemented multiple cross-displacement amplification and nanoparticles based biosensor. Artif Cells Nanomed Biotechnol. 2017: 1–14. https://doi.org/10.1080/21691401.2017.1375948 PMID: 29037087

12. Ang GY, Yu CY, Chan KG, Singh KK, Chan Yean Y. Development of a dry-reagent-based nucleic acid-sensing platform by coupling thermostabilised LATE-PCR assay to an oligonucleotide-modified lateral flow biosensor. J Microbiol Methods. 2015; 118: 99–105. https://doi.org/10.1016/j.mimet.2015.08.024 PMID: 26342435

13. Chen Y, Cheng N, Xu Y, Huang K, Luo Y, Xu W. Point-of-care and visual detection of *P. aeruginosa* and its toxin genes by multiple LAMP and lateral flow nucleic acid biosensor. Biosens Bioelectron. 2016; 81: 317–323. https://doi.org/10.1016/j.bios.2016.03.006 PMID: 26985584

14. Toubanaki DK, Athanasiou E, Karagouni E. Gold nanoparticle-based lateral flow biosensor for rapid visual detection of *Leishmania*-specific DNA amplification products. J Microbiol Methods. 2016; 127: 51–58. https://doi.org/10.1016/j.mimet.2016.05.027 PMID: 27255490

15. Wang Y, Wang Y, Xu J, Ye C. Development of Multiple Cross Displacement Amplification Label-Based Gold Nanoparticles Lateral Flow Biosensor for Detection of *Shigella* spp. Front Microbiol. 2016; 7: 1834. https://doi.org/10.3389/fmicb.2016.01834 PMID: 27917160

16. Dong D, Liu W, Li H, Wang Y, Li X, Zou D, et al. Survey and rapid detection of *Klebsiella pneumoniae* in clinical samples targeting the rcsA gene in Beijing, China. Front Microbiol. 2015; 6: 519. https://doi.org/10.3389/fmicb.2015.00519 PMID: 26052327

17. Liu D, Zhao B, Ou X, Zheng H, Ma A, He W, et al. A novel isothermal amplification-based method to detect *Mycobacterium tuberculosis* complex. J Microbiol Methods. 2018; 145: 59–65. https://doi.org/10.1016/j.mimet.2017.11.003 PMID: 29109010

18. Zweigner J, Gastmeier P, Kola A, Klefisch FR, Schweizer C, Hummel M. A carbapenem-resistant *Klebsiella pneumoniae* outbreak following bronchoscopy. Am J Infect Control. 2014; 42(8): 936–937. https://doi.org/10.1016/j.ajic.2014.04.022 PMID: 24939515

19. Nakano R, Nakano A, Ishii Y, Ubagai T, Kikuchi-Ueda T, Kikuchi H, et al. Rapid detection of the *Klebsiella pneumoniae* carbapenemase (KPC) gene by loop-mediated isothermal amplification (LAMP). J Infect Chemother. 2015; 21(3): 202–206. https://doi.org/10.1016/j.jiac.2014.11.010 PMID: 25529001

20. Kim HJ, Kim HS, Lee JM, Yoon SS, Yong D. Rapid Detection of *Pseudomonas aeruginosa* and Acinetobacter baumannii Harboring bla*VIM-2*, bla*IMP-1*, and bla*OXA-23* Genes by Using Loop-Mediated Isothermal
21. Soo P-C, Tseng C-C, Ling S-R, Liou M-L, Liu C-C, Chao H-J, et al. Rapid and sensitive detection of Acinetobacter baumannii using loop-mediated isothermal amplification. J Microbiol Methods. 2013; 92(2): 197–200. https://doi.org/10.1016/j.mimet.2012.11.020 PMID: 23220188

22. Wang Y, Li H, Wang Y, Xu H, Xu J, Ye C. Antarctic thermostable uracil-DNA-glycosylase-supplemented multiple cross displacement amplification using a label-based nanoparticle lateral flow biosensor for the simultaneous detection of nucleic acid sequences and elimination of carryover contamination. Nano Res. 2018; 11(5): 2632–2647. https://doi.org/10.1007/s12274-017-1893-z

23. McCallum KL, Whitfield C. The rcsA gene of Klebsiella pneumoniae O1:K20 is involved in expression of the serotype-specific K (capsular) antigen. Infect Immun. 1991; 59(2): 494–502. PMID: 1987069

24. Wang Y, Wang Y, Zhang L, Liu D, Luo L, Li H, et al. Multiplex, Rapid, and Sensitive Isothermal Detection of Nucleic-Acid Sequence by Endonuclease Restriction-Mediated Real-Time Multiple Cross Displacement Amplification. Front Microbiol. 2016; 7: 753. https://doi.org/10.3389/fmicb.2016.00753 PMID: 27242766

25. Misawa Y, Yoshida A, Saito R, Yoshida H, Okuzumi K, Ito N, et al. Application of loop-mediated isothermal amplification technique to rapid and direct detection of methicillin-resistant Staphylococcus aureus (MRSA) in blood cultures. J Infect Chemother. 2007; 13(3): 134–140. https://doi.org/10.1007/s10156-007-0508-9 PMID: 17593498

26. Pandey B, Poudel A, Yoda T, Tamaru A, Oda N, Fukushima Y, et al. Development of an in-house loop-mediated isothermal amplification (LAMP) assay for detection of Mycobacterium tuberculosis and evaluation in sputum samples of Nepalese patients. J Med Microbiol. 2008; 57(4): 439–443.